Cellectis S.A. (CLLS): Price and Financial Metrics
Cellectis S.A. (CLLS)
Today's Latest Price: $27.79 USD
Updated Jan 27 4:00pm
Add CLLS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CLLS Stock Summary
- With a price/sales ratio of 14.97, Cellectis SA has a higher such ratio than 87.48% of stocks in our set.
- With a year-over-year growth in debt of 133.44%, Cellectis SA's debt growth rate surpasses 90.47% of about US stocks.
- Revenue growth over the past 12 months for Cellectis SA comes in at 241.74%, a number that bests 97.3% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CLLS, based on their financial statements, market capitalization, and price volatility, are AGIO, NERV, CYCN, SURF, and DRNA.
- CLLS's SEC filings can be seen here. And to visit Cellectis SA's official web site, go to www.cellectis.com.
CLLS Stock Price Chart Interactive Chart >
CLLS Price/Volume Stats
| Current price | $27.79 | 52-week high | $34.71 |
| Prev. close | $30.11 | 52-week low | $7.32 |
| Day low | $27.31 | Volume | 368,772 |
| Day high | $29.57 | Avg. volume | 407,151 |
| 50-day MA | $27.60 | Dividend yield | N/A |
| 200-day MA | $19.81 | Market Cap | 1.18B |
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
Loading social stream, please wait...